Eli Lilly to test weight loss drugs

Lilly to offer single-dose vials of weight-loss drug on telehealth platform Ro
By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity, becoming the first alternative platform for the lower-cost version of the drug to Lilly's own website.
Eli Lilly to test weight loss drugs as addiction treatments
Eli Lilly will launch studies to investigate whether its weight loss medications can help control addictive behaviors such as smoking and alcohol and drug abuse, CEO Dave Ricks revealed in a Dec. 10 interview, Bloomberg reported.
What can't weight-loss meds do? Eli Lilly is going to test Zepbound as a treatment for addiction
Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster drug as a treatment for alcohol and drug addiction starting next year.
Zepbound: The new weight loss pill that’s set to beat Wegovy, according to Eli Lilly
Eli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on average. While both drugs showed significant weight loss benefits, Zepbound's results were more promising.
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.
Telehealth firm Ro to provide single-dose vials of Lilly's Zepbound to obesity patients
Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity.
Daily Reporter14h
Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025
For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...
The Motley Fool5d
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Eli Lilly and Novo Nordisk dominate the market for weight loss drugs, and demand for their products has surpassed supply in recent times. Lilly’s weight loss portfolio has already ...
SchaeffersResearch.com7d
Eli Lilly Touts Upbeat Weight-Loss Drug Results
Per a news release, Eli Lilly's Zepbound is more effective than Novo Nordisk's Wegovy The weight-loss drug market is about to get even more crowded. Eli Lilly & Co (NYSE:LLY) stock is up 2 ...
MarketWatch7d
Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy
Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study.
ABC News7d
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Both Ozempic, made by Novo Nordisk, and Mounjaro, made by Eli Lilly, are FDA-approved to treat Type 2 diabetes, but some doctors prescribe the medication "off-label" for weight loss, as is ...
USA Today7d
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said on Wednesday ... Zepbound helped patients lose an average of 20% of their weight after 72 weeks compared to 14% for the group treated with Wegovy, Lilly said. Participants ...